Authors Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D
Blood Nov 2013
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.Authors Cluzeau T, Mounier N, Karsenti JM, Richez V, Legros L, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Gabriel Fuzibet J, Auberger P, Raynaud S, Cassuto JP
American journal of hematology Sep 2013
Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties.Authors Bertero T, Bourget-Ponzio I, Puissant A, Loubat A, Mari B, Meneguzzi G, Auberger P, Barbry P, Ponzio G, Rezzonico R
Cell cycle (Georgetown, Tex.) Jul 2013
Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines.Authors Dufies M, Cassuto O, Jacquel A, Robert G, Auberger P
Cell cycle (Georgetown, Tex.) Jun 2013
Nepheliosyne B, a new polyacetylenic acid from the new caledonian marine sponge Niphates sp.Authors Legrave N, Hamrouni-Buonomo S, Dufies M, Guérineau V, Vacelet J, Auberger P, Amade P, Mehiri M
Marine drugs Jun 2013
Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death.Authors Ben-Sahra I, Dirat B, Laurent K, Puissant A, Auberger P, Budanov A, Tanti JF, Bost F
Cell death and differentiation Apr 2013
Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.Authors Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G
Haematologica Feb 2013
How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments.Authors Cluzeau T, Robert G, Jacquel A, Auberger P
Current pharmaceutical design Jan 2013
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.Authors Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P
Oncotarget Dec 2012
Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.Authors Robert G, Jullian V, Jacquel A, Ginet C, Dufies M, Torino S, Pottier A, Peyrade F, Tartare-Deckert S, Bourdy G, Deharo E, Auberger P
Oncotarget Dec 2012